Genufood Energy Enzymes Corp.

2023 Q4 Form 10-Q Financial Statement

#000121390024015210 Filed on February 20, 2024

View on sec.gov

Income Statement

Concept 2023 Q4 2022 Q4

Balance Sheet

Concept 2023 Q4 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.62K $46.53K
YoY Change -57.83% -83.83%
Cash & Equivalents $19.62K $46.53K
Short-Term Investments
Other Short-Term Assets $8.000K $6.660K
YoY Change 20.12% -63.75%
Inventory
Prepaid Expenses $8.000K
Receivables
Other Receivables
Total Short-Term Assets $27.62K $53.18K
YoY Change -48.07% -82.63%
LONG-TERM ASSETS
Property, Plant & Equipment $96.14K $15.01K
YoY Change 540.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $96.14K $15.01K
YoY Change 540.52%
TOTAL ASSETS
Total Short-Term Assets $27.62K $53.18K
Total Long-Term Assets $96.14K $15.01K
Total Assets $123.8K $68.19K
YoY Change 81.49% -77.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $111.8K $118.5K
YoY Change -5.59% 21.61%
Accrued Expenses $37.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $116.3K $252.7K
YoY Change -53.96% 94.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $32.98K $29.98K
YoY Change 10.01% 11.12%
Total Long-Term Liabilities $32.98K $29.98K
YoY Change 10.01% 11.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $116.3K $252.7K
Total Long-Term Liabilities $32.98K $29.98K
Total Liabilities $149.3K $282.7K
YoY Change -47.18% 80.36%
SHAREHOLDERS EQUITY
Retained Earnings -$10.60M
YoY Change
Common Stock $808.9K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$25.54K -$214.5K
YoY Change
Total Liabilities & Shareholders Equity $123.8K $68.19K
YoY Change 81.49% -77.72%

Cashflow Statement

Concept 2023 Q4 2022 Q4

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
usd
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
CY2023Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q4 us-gaap Revenues
Revenues
usd
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
299686921 shares
CY2023Q4 dei Document Type
DocumentType
10-Q
CY2023Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q4 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023Q4 dei Entity File Number
EntityFileNumber
000-56112
CY2023Q4 dei Entity Registrant Name
EntityRegistrantName
GENUFOOD ENERGY ENZYMES CORP.
CY2023Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
1108 S. Baldwin Avenue
CY2023Q4 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 107
CY2023Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Arcadia
CY2023Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91007
CY2023Q4 dei City Area Code
CityAreaCode
(855)
CY2023Q4 dei Local Phone Number
LocalPhoneNumber
707-2077
CY2023Q4 dei Security12b Title
Security12bTitle
N/A
CY2023Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q4 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q4 dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
808900041 shares
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19617 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
125924 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8000 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8187 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
27617 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
134111 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
96142 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
67451 usd
CY2023Q4 us-gaap Assets
Assets
123759 usd
CY2023Q3 us-gaap Assets
Assets
201562 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
111849 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
100849 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
37 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
37 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
116323 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
115616 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
32976 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
32226 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
808900041 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
808900041 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
808900041 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
808900041 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
808900 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
808900 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
17008342 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
16989592 usd
CY2023Q4 gfoo Discounts On Common Stock
DiscountsOnCommonStock
7241581 usd
CY2023Q3 gfoo Discounts On Common Stock
DiscountsOnCommonStock
7241581 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10601201 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10503191 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-25540 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
53720 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
123759 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
201562 usd
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
95616 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
148995 usd
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
95616 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
148995 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-95616 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-148995 usd
CY2023Q4 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-44 usd
CY2022Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-43 usd
CY2023Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-750 usd
CY2022Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-750 usd
CY2023Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-794 usd
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-793 usd
CY2023Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-96410 usd
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-149788 usd
CY2023Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1600 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-98010 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-149788 usd
CY2022Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-85 usd
CY2023Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-98010 usd
CY2022Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-149873 usd
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
808900041 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
299686921 shares
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
53720 usd
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18750 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-98010 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-25540 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-98010 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-149788 usd
CY2023Q4 us-gaap Share Based Compensation
ShareBasedCompensation
18750 usd
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
18750 usd
CY2023Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-187 usd
CY2022Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-7836 usd
CY2023Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
11000 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
17401 usd
CY2023Q4 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-10293 usd
CY2022Q4 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
30182 usd
CY2023Q4 gfoo Increase Decrease Incommitments And Contingencies
IncreaseDecreaseIncommitmentsAndContingencies
750 usd
CY2022Q4 gfoo Increase Decrease Incommitments And Contingencies
IncreaseDecreaseIncommitmentsAndContingencies
750 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-77616 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-74869 usd
CY2023Q4 us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
28691 usd
CY2022Q4 us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
15005 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-28691 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15005 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-106307 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-89874 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
125924 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
136400 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19617 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46526 usd
CY2023Q4 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1600 usd
CY2023Q4 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><b>Use of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The preparation of the condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q4 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><b>Concentrations of Credit Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Financial instruments that potentially subject the Company to significant concentrations of credit risk consisted primarily of cash, to the extent balances exceeded limits that were insured by the Federal Deposit Insurance Corporation. The Company does not require collateral and maintains reserves for potential credit losses. Such losses have historically been immaterial and have been within management’s expectations.</span></p>
CY2022Q3 gfoo Average Exchange Rate
AverageExchangeRate
0.697
CY2022Q4 gfoo Average Exchange Rates
AverageExchangeRates
0.7214
CY2023Q4 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2023Q4 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.50 pure
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10601201 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10503191 usd
CY2023 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
362000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
96142 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
67451 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
375000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
375000 usd
CY2023Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
13000 usd
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
134213120 shares
CY2023Q1 gfoo Stock Issued During Value Issuance Of Common Stock For Debt Conversion
StockIssuedDuringValueIssuanceOfCommonStockForDebtConversion
134213 usd
CY2023Q1 us-gaap Share Price
SharePrice
0.001
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5312500 shares
CY2023Q4 us-gaap Share Based Compensation
ShareBasedCompensation
18750 usd
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
18750 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0299 pure
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
3.7935 pure
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15000000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.01
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15000000 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.01
CY2023Q4 gfoo Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms
P8Y6M
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
15000000 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.01
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
5312500 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.01
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y6M
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
190428 usd
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M14D
CY2023Q4 us-gaap Capital Units Net Amount
CapitalUnitsNetAmount
10000 usd
CY2021Q3 gfoo Penalty Received
PenaltyReceived
25000 usd
CY2020 us-gaap Participating Policy Percentage Of Premium Income
ParticipatingPolicyPercentageOfPremiumIncome
0.25 pure
CY2023Q4 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
7976 usd
CY2023Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
32976 usd
CY2023Q4 us-gaap Operating Lease Payments
OperatingLeasePayments
200 usd
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
25000 usd
CY2020 gfoo Rate Of Return Percentage
RateOfReturnPercentage
0.25 pure
CY2023Q4 dei Security Exchange Name
SecurityExchangeName
NONE
CY2023Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q4 us-gaap Revenues
Revenues
usd
CY2022Q4 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
usd
CY2023Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
usd
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
808900041 shares
CY2023Q4 us-gaap Interest Paid
InterestPaid
usd
CY2022Q4 us-gaap Interest Paid
InterestPaid
usd
CY2022Q4 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
CY2023Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q4 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2023Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
shares
CY2023Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
usd
CY2023Q4 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2023Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001510518
CY2023Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2023Q4 dei No Trading Symbol Flag
NoTradingSymbolFlag
true

Files In Submission

Name View Source Status
0001213900-24-015210-index-headers.html Edgar Link pending
0001213900-24-015210-index.html Edgar Link pending
0001213900-24-015210.txt Edgar Link pending
0001213900-24-015210-xbrl.zip Edgar Link pending
f10q1223ex31-1_genufood.htm Edgar Link pending
f10q1223ex31-2_genufood.htm Edgar Link pending
f10q1223ex32-1_genufood.htm Edgar Link pending
f10q1223ex32-2_genufood.htm Edgar Link pending
f10q1223_genufood.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gfoo-20231231.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
gfoo-20231231_cal.xml Edgar Link unprocessable
gfoo-20231231_def.xml Edgar Link unprocessable
gfoo-20231231_lab.xml Edgar Link unprocessable
gfoo-20231231_pre.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
f10q1223_genufood_htm.xml Edgar Link completed